The cannabinoid CB 1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus

The effects of the selective cannabinoid CB 1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1 H-pyrazole-3-carboxamide-hydrochloride (SR141716A) on extracellular concentrations of norepinephrine and 5-hydroxytryptamine (5-HT) were assessed by in vivo micro...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of pharmacology Vol. 426; no. 3; pp. R3 - R4
Main Authors Tzavara, Eleni T, Perry, Kenneth W, Rodriguez, Dana E, Bymaster, Frank P, Nomikos, George G
Format Journal Article
LanguageEnglish
Published Elsevier B.V 2001
Subjects
Microdialysis
Norepinephrine
SR141716A
Microdialysis
Norepinephrine
SR141716A
Online AccessGet full text

Cover

More Information
Summary:The effects of the selective cannabinoid CB 1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1 H-pyrazole-3-carboxamide-hydrochloride (SR141716A) on extracellular concentrations of norepinephrine and 5-hydroxytryptamine (5-HT) were assessed by in vivo microdialysis in the anterior hypothalamus of freely moving rats. SR14716A (0.3, 1, 3 mg/kg, i.p.) dose-dependently increased norepinephrine efflux to about 300% of baseline, without affecting 5-HT levels. This increase in norepinephrine outflow could play an important role in the pharmacological and potentially therapeutic actions of SR141716A.
ISSN:0014-2999
1879-0712
DOI:10.1016/S0014-2999(01)01228-6